CUMULATIVE SUPPLEMENT 2
February 2011



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Cumulative Supplement 2

February 2011

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

CUMULATIVE SUPPLEMENT 2
February 2011

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2010	MAR 2011	JUN 2011	SEPT 2011	DEC 2011
DRUG PRODUCTS LISTED	13838				
SINGLE SOURCE	2482 (17.9%)				
MULTISOURCE	11267 (81.4%)				
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)				
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)				
EXCEPTIONS[1]	89 (0.6%)				
NEW MOLECULAR ENTITIES APPROVED	8				
NUMBER OF APPLICANTS	752				

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	AA	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>	AB	BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
>A>	AA		300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
	AB		300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA
>D>	AB		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
>A>	AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
	AB		300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA
>D>	AB		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
>A>	AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
	AB		300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA
>D>		MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
>A>	AA		300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
>D>		+	300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
>A>	AA	+	300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
>D>		+	300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC
>A>	AA	+	300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC

LORTAB

	AA	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

		@ XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC

DARVOCET-N 50

		@ XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	AB	GENPHARM	200MG	A074977	001	Apr 13, 1998	Feb	CAHN
>A>	AB	MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN

TABLET; ORAL

ACYCLOVIR

>D>	AB	GENPHARM	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
>D>	AB		800MG	A074976	002	Apr 13, 1998	Feb	CAHN
>A>	AB	MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
>A>	AB		800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	HOSPIRA	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC
>A>		@	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

>D>	AB	GENPHARM ULC	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
>D>	AB		EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
>A>	AB	MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
>A>	AB		EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

>A>	AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
>A>	AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

	AB	NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Jan	CFTG
	AB	+	EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

>D>		@ AM ANTIBIOTICS	250MG	A062058	001		Feb	CDFR
>A>	AB		250MG	A062058	001		Feb	CDFR
>D>		@	500MG	A062058	002		Feb	CDFR
>A>	AB		500MG	A062058	002		Feb	CDFR

>A> AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

>A> CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL
>A> OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>A>	+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Feb	NEWA

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

>A>	AB	SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN
>D>	AB	STASON PHARMS	1MG	A078944	001	Jun 28, 2010	Feb	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

>D>	AB	ACTAVIS TOTOWA	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN
>A>	AB	PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D>	AB	ACTAVIS TOTOWA	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN
>A>	AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

>A>	AA		COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA

PERCODAN

>D>		+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG
>A>	AA	+		325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

>D>	AB		GENPHARM	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
>D>	AB			50MG	A074126	001	Mar 23, 1994	Feb	CAHN
>D>	AB			100MG	A074126	002	Mar 23, 1994	Feb	CAHN
>A>	AB		MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
>A>	AB			50MG	A074126	001	Mar 23, 1994	Feb	CAHN
>A>	AB			100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

	AB		GLENMARK GENERICS	250MG;100MG	A091211	001	Jan 12, 2011	Jan	NEWA

MALARONE

	AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG

>A> AZILSARTAN MEDOXOMIL

>A> TABLET; ORAL

>A> EDARBI

>A>			TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
>A>		+		80MG	N200796	002	Feb 25, 2011	Feb	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

>A>		+	FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
>D>		+	NYCOMED US	500 UNITS/GM	A061212	001		Feb	CAHN
		+		500 UNITS/GM	A061212	001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

>A>	AT		FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
>D>	AT		NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
	AT			400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

>A>	AT		FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
>D>	AT		NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
	AT			500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

>A>		+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
>D>		+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
		+		400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

>D>			CNS THERAP	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
>D>				0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
>D>				2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC
>A>	AP		CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
>A>	AP			0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
>A>	AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC

LIORESAL

>D>		+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
>A>	AP	+		0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
>D>		+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
>A>	AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
>D>		+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC
>A>	AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

>D>	AB		ACTAVIS TOTOWA	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
>D>	AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN
>A>	AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
>A>	AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB		GENPHARM	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
>D>	AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN
>D>	AB			20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
>D>	AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN
>A>	AB		MYLAN	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
>A>	AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN
>A>	AB			20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
>A>	AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

>A>	AP		LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN
>D>	AP		PHARMAFORCE	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

			@ JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL
SINEMET

AB		MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN
AB			25MG;100MG	N017555	003		Jan	CAHN
AB	+		25MG;250MG	N017555	002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

AB		MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	CAHN
AB	+		50MG;200MG	N019856	001	May 30, 1991	Jan	CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

>D>	AA	ACTAVIS TOTOWA	350MG	A040188	001	Mar 07, 1997	Feb	CAHN
>A>	AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL
CEFPODOXIME PROXETIL

AB	+	SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD

VANTIN

		@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC

TABLET; ORAL
VANTIN
@ PHARMACIA AND UPJOHN EQ 200MG BASE N050674 002 Aug 07, 1992 Jan DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE
AP HOSPIRA INC EQ 250MG BASE/VIAL A065230 001 Aug 02, 2005 Jan CAHN
AP EQ 500MG BASE/VIAL A065230 002 Aug 02, 2005 Jan CAHN
AP EQ 1GM BASE/VIAL A065230 003 Aug 02, 2005 Jan CAHN
AP EQ 2GM BASE/VIAL A065230 004 Aug 02, 2005 Jan CAHN

INJECTABLE; INJECTION
CEFTRIAXONE
AP HOSPIRA INC EQ 1GM BASE/VIAL A065231 001 Aug 02, 2005 Jan CAHN
AP EQ 2GM BASE/VIAL A065231 002 Aug 02, 2005 Jan CAHN
AP EQ 10GM BASE/VIAL A065232 001 Aug 02, 2005 Jan CAHN
AP + SANDOZ EQ 10GM BASE/VIAL A065168 001 May 17, 2005 Jan CRLD

CEFUROXIME SODIUM

INJECTABLE; IM-IV
CEFUROXIME SODIUM
AP HOSPIRA INC EQ 750MG BASE/VIAL A065483 001 Oct 15, 2008 Jan CAHN

INJECTABLE; INJECTION
CEFUROXIME SODIUM
AP HOSPIRA INC EQ 1.5GM BASE/VIAL A065503 001 Oct 15, 2008 Jan CAHN
AP EQ 1.5GM BASE/VIAL A065483 002 Oct 15, 2008 Jan CAHN
AP EQ 7.5GM BASE/VIAL A065484 001 Oct 15, 2008 Jan CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL
CEPHALEXIN
@ ACS DOBFAR EQ 100MG BASE/ML A062117 001 Jan CAHN
AB EQ 125MG BASE/5ML A062117 002 Jan CAHN
AB + EQ 250MG BASE/5ML A062117 003 Jan CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE
>D> AT ACTAVIS MID ATLANTIC 0.12% A074291 001 Dec 28, 1995 Feb CAHN
>A> AT LYNE 0.12% A074291 001 Dec 28, 1995 Feb CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE
AA NATCO PHARMA LTD EQ 150MG BASE A091621 001 Jan 21, 2011 Jan NEWA
AA EQ 300MG BASE A090612 001 Jan 21, 2011 Jan NEWA

CICLOPIROX

SHAMPOO; TOPICAL
CICLOPIROX
>A> AT TARO 1% A090269 001 Feb 23, 2011 Feb NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE
AP WEST WARD 1MG/10ML (0.1MG/ML) A200300 001 Jan 26, 2011 Jan NEWA

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	WEST WARD	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
>D>	AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN
	AB	JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
	AB		10MG	A077563	002	Apr 19, 2006	Jan	CAHN
>A>	AB	KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
>A>	AB		10MG	A078048	002	Feb 28, 2011	Feb	NEWA
>A>	AB	PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
>A>	AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

>A>	AB	DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

>A>	AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

>A>	AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

>A>	AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
>D>	AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
	AT		0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

>D>	AB	ACTAVIS TOTOWA	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
>D>	AB		50MG	A040542	002	Apr 21, 2006	Feb	CAHN
>D>	AB		75MG	A040542	003	Apr 21, 2006	Feb	CAHN
>A>	AB	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
>A>	AB		50MG	A040542	002	Apr 21, 2006	Feb	CAHN
>A>	AB		75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

>A>	AB		WATSON LABS FLORIDA	EQ 500MG BASE VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

	AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
	AB		MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
>D>	AB	+	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
>A>	AB	+		EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
	AB	+		EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

ENOXAPARIN SODIUM

>A> INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
>A> LOVENOX

>A>			SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

>D> INJECTABLE; SUBCUTANEOUS
>D> LOVENOX

>D>			SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
ELESTAT

>D>		+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG
>A>	AT	+		0.05%	N021565	001	Oct 16, 2003	Feb	CFTG

>A> EPINASTINE HYDROCHLORIDE

>A>	AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYTHROMYCIN

	AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

>A>	AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN
>D>	AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN
	AT	+		0.5%	A062447	001	Sep 26, 1983	Jan	CAHN

SOLUTION; TOPICAL
ERYDERM

			@ ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN

TABLET; ORAL
ERYTHROMYCIN

			ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN
		+		500MG	A061621	002		Jan	CAHN

TABLET, COATED PARTICLES; ORAL
PCE

			ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN
		+		500MG	N050611	002	Aug 22, 1990	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL
E-MYCIN

			@ ARBOR PHARMS INC	250MG	A060272	001		Jan	CAHN
			@	333MG	A060272	002		Jan	CAHN

TABLET, DELAYED RELEASE; ORAL
ERY-TAB
\+ ARBOR PHARMS INC 250MG A062298 001 Jan CAHN
\+ 333MG A062298 003 Mar 29, 1982 Jan CAHN
\+ 500MG A062298 002 Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL
E.E.S.
AB ARBOR PHARMS INC EQ 200MG BASE/5ML N050207 001 Jan CAHN
ERYPED
AB ARBOR PHARMS INC EQ 200MG BASE/5ML N050207 003 Mar 30, 1987 Jan CAHN
\+ EQ 400MG BASE/5ML N050207 002 Jan CAHN
SUSPENSION; ORAL
E.E.S. 200
AB ARBOR PHARMS INC EQ 200MG BASE/5ML A061639 001 Jan CAHN
E.E.S. 400
AB \+ ARBOR PHARMS INC EQ 400MG BASE/5ML A061639 002 Jan CAHN
PEDIAMYCIN
AB ARBOR PHARMS INC EQ 200MG BASE/5ML A062304 001 Jan CAHN
PEDIAMYCIN 400
AB ARBOR PHARMS INC EQ 400MG BASE/5ML A062304 002 Jan CAHN
TABLET; ORAL
E.E.S. 400
@ ARBOR PHARMS INC EQ 400MG BASE A061905 001 Jan CAHN
BX \+ EQ 400MG BASE A061905 002 Aug 12, 1982 Jan CAHN
ERYTHROMYCIN ETHYLSUCCINATE
BX \+ ARBOR PHARMS INC EQ 400MG BASE A061904 001 Jan CAHN
TABLET, CHEWABLE; ORAL
E.E.S.
@ ARBOR PHARMS INC EQ 200MG BASE N050297 002 Jan CAHN
ERYPED
@ ARBOR PHARMS INC EQ 200MG BASE N050297 003 Jul 05, 1988 Jan CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL
ERYTHROCIN STEARATE
@ ARBOR PHARMS INC EQ 125MG BASE A060359 002 Jan CAHN
EQ 250MG BASE A060359 001 Jan CAHN
\+ EQ 500MG BASE A060359 003 Jan CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
\+ WARNER CHILCOTT 0.025MG;0.8MG N022573 001 Dec 22, 2010 Jan CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28
GILDESS FE 1.5/30
AB VINTAGE 0.03MG;1.5MG A077075 001 Apr 28, 2005 Jan CTNA
GILDESS FE 1/20
AB VINTAGE 0.02MG;1MG A077077 001 May 20, 2005 Jan CTNA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>A>	AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA

ETODOLAC

CAPSULE; ORAL

ETODOLAC

>D>		@ GENPHARM	200MG	A075071	001	Sep 30, 1998	Feb	CAHN
>D>		@	300MG	A075071	002	Sep 30, 1998	Feb	CAHN
>A>		@ MYLAN	200MG	A075071	001	Sep 30, 1998	Feb	CAHN
>A>		@	300MG	A075071	002	Sep 30, 1998	Feb	CAHN

TABLET; ORAL

ETODOLAC

>D>		@ GENPHARM	400MG	A075012	001	Sep 30, 1998	Feb	CAHN
>D>		@	500MG	A075012	002	Sep 30, 1998	Feb	CAHN
>A>		@ MYLAN	400MG	A075012	001	Sep 30, 1998	Feb	CAHN
>A>		@	500MG	A075012	002	Sep 30, 1998	Feb	CAHN

ETRAVIRINE

TABLET; ORAL

INTELENCE

		TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan	CRLD
		+	200MG	N022187	002	Dec 22, 2010	Jan	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

PEPCID

		@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE

		@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

		@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC

TABLET; ORAL

FAMOTIDINE

>D>	AB	GENPHARM	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
>D>	AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN
>A>	AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
>A>	AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

>D>		SHIONOGI PHARMA	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
>D>		+	120MG	N022118	002	Aug 10, 2007	Feb	CAHN
>A>		SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
>A>		+	120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

	AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA

FENTANYL-25

	AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-50

AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA

FENTANYL-75

AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

TABLET; SUBLINGUAL
ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Jan	NEWA
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Jan	NEWA
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	180MG;240MG	A079043	001	Mar 17, 2010	Jan	CTEC

FLUCONAZOLE

TABLET; ORAL
FLUCONAZOLE

>A> AB	AMNEAL PHARM	50MG	A078423	001	Mar 07, 2011	Feb	NEWA
>A> AB		100MG	A078423	002	Mar 07, 2011	Feb	NEWA
>A> AB		150MG	A078423	003	Mar 07, 2011	Feb	NEWA
>A> AB		200MG	A078423	004	Mar 07, 2011	Feb	NEWA
>D> AB	GENPHARM	50MG	A076042	001	Jul 29, 2004	Feb	CAHN
>D> AB		100MG	A076042	002	Jul 29, 2004	Feb	CAHN
>D> AB		150MG	A076042	003	Jul 29, 2004	Feb	CAHN
>D> AB		200MG	A076042	004	Jul 29, 2004	Feb	CAHN
>A> AB	MYLAN	50MG	A076042	001	Jul 29, 2004	Feb	CAHN
>A> AB		100MG	A076042	002	Jul 29, 2004	Feb	CAHN
>A> AB		150MG	A076042	003	Jul 29, 2004	Feb	CAHN
>A> AB		200MG	A076042	004	Jul 29, 2004	Feb	CAHN

FLUDARABINE PHOSPHATE

TABLET; ORAL
OFORTA

	@ SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

>D>	+ FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC
>A> AP	+	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC
>A> AP	PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	Feb	NEWA

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

>D> AB	GENPHARM	125MG	A076224	001	May 09, 2003	Feb	CAHN
>A> AB	MYLAN	125MG	A076224	001	May 09, 2003	Feb	CAHN

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>D>		@ GENPHARM	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
>D>		@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN
>A>		@ MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
>A>		@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

	AA	JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

	AB	MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
	AB		300MG	A090158	002	Feb 14, 2011	Jan	NEWA
	AB		400MG	A090158	003	Feb 14, 2011	Jan	NEWA

SOLUTION; ORAL

>A>		GABAPENTIN							
>A>	AA	HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA

NEURONTIN

>D>	+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG
>A>	AA +		250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL

GABAPENTIN

	AB	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
	AB		800MG	A078926	002	Feb 11, 2011	Jan	NEWA

GRALISE

	BX +	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jan	NEWA
	BX +		600MG	N022544	002	Jan 28, 2011	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

	AB	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
	AB		EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
	AB		EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
	AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
	AB		EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
	AB		EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
	AB		EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
	AB		EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

>D>		HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD
>A>	+		EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD

GEMCITABINE HYDROCHLORIDE

	AP	TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP		TEVA PARENTERAL	EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

>A>	AB	BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN
>D>	AB	PERRIGO R AND D	600MG	A078012	001	Mar 26, 2007	Feb	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

>A>	AT	FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
>D>	AT	NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
	AT		EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

>D>	AT	ALTANA	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN
>A>	AT	FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

>D>	AB	GENPHARM	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
>D>	AB		2MG	A077486	002	Feb 10, 2006	Feb	CAHN
>D>	AB		4MG	A077486	003	Feb 10, 2006	Feb	CAHN
>A>	AB	MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
>A>	AB		2MG	A077486	002	Feb 10, 2006	Feb	CAHN
>A>	AB		4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

GLYBURIDE

TABLET; ORAL
GLYBURIDE

>A>	AB	INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
>A>	AB		2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA
>A>	AB		5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
FULVICIN P/G

		@ ELORAC	125MG	A061996	001		Jan	CAHN
		@	250MG	A061996	002		Jan	CAHN

FULVICIN P/G 165

		@ ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN

TABLET; ORAL
FULVICIN P/G 330
@ ELORAC 330MG A061996 004 Apr 06, 1982 Jan CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE
AB JUBILANT CADISTA 12.5MG A078391 001 Feb 11, 2008 Jan CAHN

TABLET; ORAL
HYDROCHLOROTHIAZIDE
AB JUBILANT CADISTA 25MG A040809 001 Sep 04, 2007 Jan CAHN
AB 50MG A040809 002 Sep 04, 2007 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
AB WATSON LABS 12.5MG;50MG A200180 001 Jan 12, 2011 Jan NEWA
AB 12.5MG;100MG A200180 002 Jan 12, 2011 Jan NEWA
AB 25MG;100MG A200180 003 Jan 12, 2011 Jan NEWA

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL
HYDROMORPHONE HYDROCHLORIDE
>A> AB ELITE LABS 8MG A076723 001 Oct 18, 2005 Feb CAHN
>D> AB MIKAH PHARMA 8MG A076723 001 Oct 18, 2005 Feb CAHN

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREDRINE
@ PHARMICS 1% N000004 004 Jan CAHN

>A> HYDROXYPROGESTERONE CAPROATE

>A> SOLUTION; INTRAMUSCULAR
>A> MAKENA
>A> + KV PHARM 1250MG/5ML (250MG/ML) N021945 001 Feb 03, 2011 Feb NEWA

ILOPERIDONE

TABLET; ORAL
FANAPT
NOVARTIS 2MG N022192 002 May 06, 2009 Jan CAHN
4MG N022192 003 May 06, 2009 Jan CAHN
6MG N022192 004 May 06, 2009 Jan CAHN
8MG N022192 005 May 06, 2009 Jan CAHN
10MG N022192 006 May 06, 2009 Jan CAHN

IMIQUIMOD

CREAM; TOPICAL
IMIQUIMOD
>A> AB TOLMAR 5% A091044 001 Feb 28, 2011 Feb NEWA

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN
AB + SANDOZ 75MG A074464 001 May 28, 1998 Jan CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+		GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA	

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

>D>	AP		HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC
>A>			@	41%	A074898	001	Dec 30, 1997	Feb	DISC

>D> IOPAMIDOL-200 IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC
>A>			@	41%	A074636	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250

>D>	AP		HOSPIRA	51%	A074898	002	Dec 30, 1997	Feb	DISC
>A>			@	51%	A074898	002	Dec 30, 1997	Feb	DISC

>D> IOPAMIDOL-250 IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC
>A>			@	51%	A074636	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300

>D>	AP		HOSPIRA	61%	A074898	003	Dec 30, 1997	Feb	DISC
>A>			@	61%	A074898	003	Dec 30, 1997	Feb	DISC

>D> IOPAMIDOL-300 IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	61%	A074636	003	Dec 30, 1997	Feb	DISC
>A>			@	61%	A074636	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370

>D>	AP		HOSPIRA	76%	A074898	004	Dec 30, 1997	Feb	DISC
>A>			@	76%	A074898	004	Dec 30, 1997	Feb	DISC

>D> IOPAMIDOL-370 IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC
>A>			@	76%	A074636	004	Dec 30, 1997	Feb	DISC

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

>D>	AB		ACTAVIS TOTOWA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
>D>	AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN
>A>	AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
>A>	AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

	AB		ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
	AB			100MG	A090607	002	Jan 13, 2011	Jan	NEWA
	AB			150MG	A090607	003	Jan 13, 2011	Jan	NEWA
	AB			200MG	A090607	004	Jan 13, 2011	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

>A>	AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
>A>	AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

LEVETIRACETAM

TABLET; ORAL
LEVETIRACETAM

	AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
	AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
	AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
	AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	AB	DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
>A>	AB	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
LEVOFLOXACIN

	AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA

LEVONORGESTREL

TABLET; ORAL
PLAN B

>D>		@ DURAMED	0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN
>D>	AB	+	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN
>A>	AB	+ TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN
>A>		@	0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL
LEVO-T

>D>	AB2, AB3	ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC

TABLET; ORAL
LEVO-T

>D>	AB2, AB3	ALARA PHARM	0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
>A>	AB1, AB2, AB3		0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
>D>	AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
>D>	AB2, AB3		0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC
>A>	AB1, AB2, AB3		0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC
>D>	AB2, + AB3		0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC
>A>	AB1, + AB2, AB3		0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

	AB	GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011	Jan	NEWA

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

	AB	MYLAN	25MG	A091590	001	Oct 06, 2010	Jan	NEWA
	AB		50MG	A091590	002	Oct 06, 2010	Jan	NEWA
	AB		100MG	A091590	003	Oct 06, 2010	Jan	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

>A>	AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Feb	NEWA
>A>	AA		25MG	A201451	002	Feb 23, 2011	Feb	NEWA
>A>	AA		50MG	A201451	003	Feb 23, 2011	Feb	NEWA
	AA	JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN
	AA		25MG	A040659	002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL
MELOXICAM

>D>	AB	GENPHARM	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
>D>	AB		15MG	A077934	002	Jul 20, 2006	Feb	CAHN
>A>	AB	MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
>A>	AB		15MG	A077934	002	Jul 20, 2006	Feb	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

>D>	AB	GENPHARM	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
>D>	AB		850MG	A075973	002	Jan 25, 2002	Feb	CAHN
>D>	AB		1GM	A075973	003	Jan 25, 2002	Feb	CAHN
>A>	AB	MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
>A>	AB		850MG	A075973	002	Jan 25, 2002	Feb	CAHN
>A>	AB		1GM	A075973	003	Jan 25, 2002	Feb	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOPLUS MET

>D>		TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
>A>	AB		500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
>D>	+		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG
>A>	AB +		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

>A> PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>A>	AB	MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
>A>	AB		850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

	AB	JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
	AB		8MG	A040189	002	Oct 31, 1997	Jan	CAHN
	AB		16MG	A040189	003	Jul 20, 2007	Jan	CAHN
	AB		32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
>A>		@	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
>D>	AP		EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC
>A>		@	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE

	AB	G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

	+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

>D>	AP	HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC
>A>		@	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB		ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA
AB			30MG	A077959	002	Feb 14, 2011	Jan	NEWA
AB			45MG	A077959	003	Feb 14, 2011	Jan	NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR

NABUMETONE

TABLET; ORAL

NABUMETONE

AB		LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
AB			750MG	A090445	002	Jan 12, 2011	Jan	NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

>A>	AB	ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN
>D>	AB	MIKAH PHARMA	50MG	A075274	001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL

NAPROXEN

AB		MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
AB			375MG	A091416	002	Feb 14, 2011	Jan	NEWA
AB			500MG	A091416	003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

>A>	AB	INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
>A>	AB		EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB			17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB			25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB			34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

>D>	AB	GENPHARM	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
>D>	AB		300MG	A075934	002	Jul 09, 2002	Feb	CAHN
>A>	AB	MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
>A>	AB		300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

>A>	AA	VISTAPHARM	100,000 UNITS/ML	A065422	001	Mar 07, 2011	Feb	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)

	AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Jan	NEWA
	AP		EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Jan	NEWA
	AP		EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Jan	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

>A>	AB	RANBAXY	4MG	A078602	001	Feb 24, 2011	Feb	NEWA
>A>	AB		8MG	A078602	002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

	AP	TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Jan	CMFD

SOLUTION; ORAL
ONDANSETRON HYDROCHLORIDE

	AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
	AA	SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

	AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
	AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

>D>	AB	GENPHARM	600MG	A075847	001	Feb 28, 2001	Feb	CAHN
>A>	AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

>A>	AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
>A>	AB		15MG	A091313	002	Feb 18, 2011	Feb	NEWA
>A>	AB		30MG	A091313	003	Feb 18, 2011	Feb	NEWA
>A>	AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
>A>	AB		10MG	A091490	002	Mar 09, 2011	Feb	NEWA

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

>A>	AB	RHODES PHARMS	15MG	A091490	003	Mar 09, 2011	Feb	NEWA
>A>	AB		20MG	A091490	004	Mar 09, 2011	Feb	NEWA
>A>	AB		30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

	AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
	AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

>D>	AB	ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
>A>		@	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
>D>	AB		15MG	N021610	006	Feb 29, 2008	Feb	DISC
>A>		@	15MG	N021610	006	Feb 29, 2008	Feb	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

	AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA
	AB	KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Jan	NEWA
	AB	MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090970	002	Jan 19, 2011	Jan	NEWA
	AB	TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090074	002	Jan 19, 2011	Jan	NEWA
	AB	WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A091231	002	Jan 19, 2011	Jan	NEWA

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE

	AA	EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

	AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN

PIROXICAM

CAPSULE; ORAL
PIROXICAM

>D>		@ GENPHARM	10MG	A074043	001	Sep 22, 1992	Feb	CAHN
>D>		@	20MG	A074043	002	Sep 22, 1992	Feb	CAHN
>A>		@ MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN

CAPSULE; ORAL
PIROXICAM

>A>		@ MYLAN	20MG	A074043	002	Sep 22, 1992	Feb	CAHN

PREDNISONE

TABLET; ORAL
PREDNISONE

	AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
	AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN
	AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN
	AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCOMP

	AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN
	AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

	+	ROXANE	15MG	A080927	002		Jan	CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

		@ XANODYNE PHARM	65MG	N010997	003		Jan	DISC

PROPOXYPHENE HYDROCHLORIDE

		@ WEST WARD	65MG	A083501	001		Jan	DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVON-N

		@ XANODYNE PHARM	100MG	N016862	002		Jan	DISC

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

>D>	AB	GENPHARM	EQ 5MG BASE	A076036	001	Jan 28, 2005	Feb	CAHN
>D>	AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Feb	CAHN
>D>	AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Feb	CAHN
>D>	AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Feb	CAHN
>A>	AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Feb	CAHN
>A>	AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Feb	CAHN
>A>	AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Feb	CAHN
>A>	AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Feb	CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HYDROCHLORIDE

>D>		@ GENPHARM	EQ 150MG BASE	A075564	001	Oct 27, 2000	Feb	CAHN
>D>		@	EQ 300MG BASE	A075564	002	Oct 27, 2000	Feb	CAHN
>A>		@ MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000	Feb	CAHN
>A>		@	EQ 300MG BASE	A075564	002	Oct 27, 2000	Feb	CAHN

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

>D>	AB	GENPHARM	EQ 150MG BASE	A074023	001	Aug 22, 1997	Feb	CAHN
>D>	AB		EQ 300MG BASE	A074023	002	Aug 22, 1997	Feb	CAHN
>A>	AB	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997	Feb	CAHN
>A>	AB		EQ 300MG BASE	A074023	002	Aug 22, 1997	Feb	CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN

>D>		SALIX PHARMS	550MG	N022554	001	Mar 24, 2010	Feb	CRLD
>A>	+		550MG	N022554	001	Mar 24, 2010	Feb	CRLD

RISPERIDONE

SOLUTION; ORAL
RISPERIDONE

	AA	TARO	1MG/ML	A090347	001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL
RISPERIDONE

>D>	AB	RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
>A>		@	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
>D>	AB		0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
>A>		@	0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
>D>	AB		1MG	A077784	003	Jun 08, 2010	Feb	DISC
>A>		@	1MG	A077784	003	Jun 08, 2010	Feb	DISC
>D>	AB		2MG	A077784	004	Jun 08, 2010	Feb	DISC
>A>		@	2MG	A077784	004	Jun 08, 2010	Feb	DISC
>D>	AB		3MG	A077784	005	Jun 08, 2010	Feb	DISC
>A>		@	3MG	A077784	005	Jun 08, 2010	Feb	DISC
>D>	AB		4MG	A077784	006	Jun 08, 2010	Feb	DISC
>A>		@	4MG	A077784	006	Jun 08, 2010	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

	AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Jan	CAHN
	AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Jan	CAHN

>A> ROFLUMILAST

>A> TABLET; ORAL
>A> DALIRESP

>A>	+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Feb	NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM

	+	MARATHON PHARMS	50MG	A086101	001	Oct 03, 1983	Jan	CAHN
	+		100MG	A086101	002	Oct 03, 1983	Jan	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

>D>	AB	GENPHARM	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
>D>	AB		EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
>D>	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
>A>	AB	MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

>A>	AB	MYLAN	EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
>A>	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F 18

	+	NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS
>A> NITHIODOTE

>A>	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA

>D> SODIUM NITRITE

>D>	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA
	+		300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA

SPINOSAD

SUSPENSION; TOPICAL
NATROBA

	+	PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

	AB	JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
	AB		EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
	AB		EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
	AB		EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

>D>	AB	GENPHARM	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN
>A>	AB	MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN
>D>	AB	ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC
>A>		@	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

	AB	+ IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

>D>	AB	GENPHARM	250MG	A075161	001	Sep 13, 1999	Feb	CAHN
>A>	AB	MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

>A>	AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA
>A>	SOLUTION; INTRAVENOUS							
>A>	TOPOTECAN							
>A> AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
>A>	SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb	NEWA
>A>		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb	NEWA
>A> AP +		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

>A> AP	PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

>A> AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
TRIMIPRAMINE MALEATE

>D> AB	ACTAVIS TOTOWA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
>D> AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
>D> AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN
>A> AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
>A> AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
>A> AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

>A> AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
>A> AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VIIBRYD

	TROVIS PHARMS	10MG	N022567	001	Jan 21, 2011	Jan	NEWA
		20MG	N022567	002	Jan 21, 2011	Jan	NEWA
+		40MG	N022567	003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

	@ APP PHARMS	1MG/ML	A076401	001	Oct 28, 2003	Jan	DISC

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE

>A> AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN
>D> AP	PHARMAFORCE	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN

TABLET; ORAL
ZIDOVUDINE

>A>		@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

>D>	AB	GENPHARM	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
>D>	AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN
>A>	AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
>A>	AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>D>		GENPHARM	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
>A>		MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+		SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+		SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+		SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+		SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA

TABLET; ORAL

ALLEGRA ALLERGY

		SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
+			180MG	N020872	010	Jan 24, 2011	Jan	NEWA

ALLEGRA HIVES

		SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
+			180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

		SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

		SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+		SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+		SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

		MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
			200MG	A091239	001	Feb 01, 2011	Jan	NEWA
		MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+		NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD

LEVONORGESTREL

TABLET; ORAL

PLAN B

>D>	+	DURAMED	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN
>A>	+	TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

>A>	MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011	Feb	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

>D>	GENPHARM	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN
>A>	MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2011

NO FEBRUARY 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO FEBRUARY 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE - DIFFERIN						
N021753 001	7868044	Mar 12, 2023	U-1078			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 002					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 003					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 004					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALVIMOPAN - ENTEREG						
N021775 001	**>A>** 5250542	Mar 29, 2016	DS DP U-878			
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE						
A078381 005					PC	Jul 02, 2011
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE						
A078381 006					PC	Jul 02, 2011
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10						
N021303 001	**>A>** RE42096	Oct 21, 2018	DP			
	>A> RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N021303 006	**>A>** RE42096	Oct 21, 2018	DP			
	>A> RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
N021303 002	**>A>** RE42096	Oct 21, 2018	DP			
	>A> RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N021303 004	**>A>** RE42096	Oct 21, 2018	DP			
	>A> RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	**>A>** RE42096	Oct 21, 2018	DP			
	>A> RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	**>A>** RE42096	Oct 21, 2018	DP			
	>A> RE42096*PED	Apr 21, 2019				
ARIPIPRAZOLE - ABILIFY						
N021436 001					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 002					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 003					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 004					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 005					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 006					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021713 001					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 002					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 003					**>A>** I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021866 001					**>A>** I-633	Feb 16, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 001					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 002					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 003					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 004					D-130	Feb 04, 2014
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 001	**>A>** 5583141	Dec 10, 2013	DS DP U-3		**>A>** NCE	Feb 25, 2016
	>A> 5736555	Jun 25, 2012	DS DP U-3			
	>A> 5958961	Jun 06, 2014	DP U-3			
	>A> 7157584	May 22, 2025	DS			
	>A> 7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 002	**>A>** 5583141	Dec 10, 2013	DS DP U-3		**>A>** NCE	Feb 25, 2016
	>A> 5736555	Jun 25, 2012	DS DP U-3			
	>A> 5958961	Jun 06, 2014	DP U-3			
	>A> 7157584	May 22, 2025	DS			
	>A> 7572920	Jan 07, 2025	DP U-3			
AZITHROMYCIN - ZMAX						
N050797 001	**>A>** 7887844	Feb 14, 2024	DP			
CELECOXIB - CELEBREX						
N020998 001	**>A>** 5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX						
N020998 002	**>A>** 5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX						
N020998 003	**>A>** 5760068	Jun 02, 2015	U-672			
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 001					**>A>** I-634	Feb 25, 2014
					>A> M-101	Feb 25, 2014
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 002					**>A>** I-634	Feb 25, 2014
					>A> M-101	Feb 25, 2014
CINACALCET HYDROCHLORIDE - SENSIPAR						
N021688 003					**>A>** I-634	Feb 25, 2014
					>A> M-101	Feb 25, 2014
CLOPIDOGREL BISULFATE - PLAVIX						
N020839 001	4847265	Nov 17, 2011	DS DP			
	4847265*PED	May 17, 2012				
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
CLOPIDOGREL BISULFATE - PLAVIX						
N020839 002	4847265	Nov 17, 2011	DS DP			
	4847265*PED	May 17, 2012				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
DESIRUDIN RECOMBINANT - IPRIVASK						
N021271 001	6103515	Aug 15, 2017	DS			
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	**>A>** 7884095	Feb 24, 2029	U-1111			
	>A> 7884095*PED	Aug 24, 2029				
DORIPENEM - DORIBAX						
N022106 001	**>A>** 5317016	Jun 05, 2015	DS DP U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DORIPENEM - DORIBAX							
N022106 002	>A>	5317016	Jun 05, 2015	DS DP U-282			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL							
N022574 001		5798338	Jul 10, 2015	DP			
		6441168	Apr 17, 2020	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022	U-1			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N022511 001	>A>	5714504	Feb 03, 2015	DP U-1053			
	>A>	5714504*PED	Aug 03, 2015				
	>A>	5900424	May 04, 2016	DS U-1053			
	>A>	5900424*PED	Nov 04, 2016				
	>A>	6369085	May 25, 2018	DS DP U-1053			
	>A>	6369085*PED	Nov 25, 2018				
	>A>	6875872	May 27, 2014	DS			
	>A>	6875872*PED	Nov 27, 2014				
	>A>	7411070	May 25, 2018	DS U-1053			
	>A>	7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N022511 002	>A>	5714504	Feb 03, 2015	DP U-1053			
	>A>	5714504*PED	Aug 03, 2015				
	>A>	5900424	May 04, 2016	DS U-1053			
	>A>	5900424*PED	Nov 04, 2016				
	>A>	6369085	May 25, 2018	DS DP U-1053			
	>A>	6369085*PED	Nov 25, 2018				
	>A>	6875872	May 27, 2014	DS			
	>A>	6875872*PED	Nov 27, 2014				
	>A>	7411070	May 25, 2018	DS U-1053			
	>A>	7411070*PED	Nov 25, 2018				
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N022262 001		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N021840 001		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
N022573 001		5552394	Jul 22, 2014	U-828			
		6667050	Apr 06, 2019	DP U-828			
ETRAVIRINE - INTELENCE							
N022187 001	>A>	7887845	Mar 25, 2019	DP			
ETRAVIRINE - INTELENCE							
N022187 002		6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
		7037917	Nov 05, 2019	DS DP U-1016			
	>A>	7887845	Mar 25, 2019	DP			
EXENATIDE SYNTHETIC - BYETTA							
N021773 001		5424286	Dec 01, 2016	U-653			
		5424286	Dec 01, 2016	U-1108			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYETTA						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
FAMCICLOVIR - FAMVIR						
N020363 001					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR						
N020363 002					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR						
N020363 003					M-98	Jan 31, 2014
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 003	**>A>** 7863331	Aug 08, 2020	U-1107			
	>A> 7863331	Aug 08, 2020	U-1106			
FENTANYL CITRATE - ABSTRAL						
N022510 001	**>A>** 6759059	Sep 24, 2019	DP U-767			
	>A> 6761910	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 002	**>A>** 6759059	Sep 24, 2019	DP U-767			
	>A> 6761910	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 003	**>A>** 6759059	Sep 24, 2019	DP U-767			
	>A> 6761910	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 004	**>A>** 6759059	Sep 24, 2019	DP U-767			
	>A> 6761910	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 005	**>A>** 6759059	Sep 24, 2019	DP U-767			
	>A> 6761910	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 006	**>A>** 6759059	Sep 24, 2019	DP U-767			
	>A> 6761910	Sep 24, 2019	DP U-767			
FERUMOXYTOL - FERAHEME						
N022180 001	7871597	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	7855230	May 11, 2019	U-913			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	7855230	May 11, 2019	U-913			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
A079043 001					PC	Jul 27, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FULVESTRANT - FASLODEX						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			PED	Mar 09, 2014
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
GABAPENTIN - GABAPENTIN						
A078974 001					**>A>** PC	Aug 22, 2011
GABAPENTIN - GRALISE						
N022544 001					NP	Jan 28, 2014
GABAPENTIN - GRALISE						
N022544 002					NP	Jan 28, 2014
GEMCITABINE HYDROCHLORIDE - GEMCITABINE						
A079183 001					PC	May 14, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 001					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 002					PC	Jul 24, 2011
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 001					**>A>** I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 002					**>A>** I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 003					**>A>** I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 004					**>A>** I-635	Feb 25, 2014
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N021945 001					**>A>** ODE	Feb 03, 2018
IOFLUPANE I-123 - DATSCAN						
N022454 001					NCE	Jan 14, 2016
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 001	5595760	Mar 08, 2020	DP U-831		**>A>** D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 002	5595760	Mar 08, 2020	DP U-831		**>A>** D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 003	5595760	Mar 08, 2020	DP U-831		**>A>** D-131	Mar 04, 2014
LANSOPRAZOLE - PREVACID						
N021428 001	**>A>** 7875292	May 17, 2019	DP			
	>A> 7875292*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
N021428 002	**>A>** 7875292	May 17, 2019	DP			
	>A> 7875292*PED	Nov 17, 2019				
LENALIDOMIDE - REVLIMID						
N021880 001	7855217	Nov 24, 2024	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 002	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 004	7855217	Nov 24, 2024	DS DP			
METRONIDAZOLE - VANDAZOLE						
N021806 001	7456207	Sep 22, 2024	DP			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 001	**>A>** 7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 002	**>A>** 7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 003	**>A>** 7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 004	**>A>** 7888342	Nov 05, 2021	U-882			
MOMETASONE FUROATE MONOHYDRATE - NASONEX						
N020762 001					M-99	Jan 19, 2014
PERFLUTREN - DEFINITY						
N021064 001	5585112	Dec 17, 2013	DP			
PLERIXAFOR - MOZOBIL						
N022311 001	**>A>** RE42152	Dec 10, 2013	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N022145 001	**>A>** 7169780	Oct 03, 2023	DS DP			
RETAPAMULIN - ALTABAX						
N022055 001	7875630	Feb 14, 2027	DS			
	>A> RE39128	Apr 12, 2021	DS DP U-805			
ROFLUMILAST - DALIRESP						
N022522 001					**>A>** NCE	Feb 28, 2016
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N201444 001					**>A>** ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM						
N021196 001	**>A>** 7668730	Jun 16, 2024	U-1110			
	>A> 7895059	Dec 17, 2022	U-1110			
SPINOSAD - NATROBA						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	**>A>** 7776007	Apr 09, 2025	DP			
TELBIVUDINE - TYZEKA						
N022011 001	**>A>** 7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 2 - February 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
TIGECYCLINE - TYGACIL						
N021821 001	7879828	Feb 05, 2029	DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm